These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
5. Advances and Limitations of Antibody Drug Conjugates for Cancer. Mckertish CM; Kayser V Biomedicines; 2021 Jul; 9(8):. PubMed ID: 34440076 [TBL] [Abstract][Full Text] [Related]
6. Pharmacokinetic Considerations for Antibody-Drug Conjugates against Cancer. Malik P; Phipps C; Edginton A; Blay J Pharm Res; 2017 Dec; 34(12):2579-2595. PubMed ID: 28924691 [TBL] [Abstract][Full Text] [Related]
7. Antibody-Drug Conjugates: A Review on the Epitome of Targeted Anti- Cancer Therapy. Hasan M; Alam S; Poddar SK Curr Clin Pharmacol; 2018; 13(4):236-251. PubMed ID: 30073930 [TBL] [Abstract][Full Text] [Related]
8. Current Status: Site-Specific Antibody Drug Conjugates. Schumacher D; Hackenberger CP; Leonhardt H; Helma J J Clin Immunol; 2016 May; 36 Suppl 1():100-7. PubMed ID: 27003914 [TBL] [Abstract][Full Text] [Related]
9. [Novel Chemical Linkers for Next-generation Antibody-drug Conjugates(ADCs)]. Tsuchikama K Yakugaku Zasshi; 2019; 139(2):209-219. PubMed ID: 30713230 [TBL] [Abstract][Full Text] [Related]
10. Linkers: An Assurance for Controlled Delivery of Antibody-Drug Conjugate. Sheyi R; de la Torre BG; Albericio F Pharmaceutics; 2022 Feb; 14(2):. PubMed ID: 35214128 [TBL] [Abstract][Full Text] [Related]
13. Toward a Ferrous Iron-Cleavable Linker for Antibody-Drug Conjugates. Spangler B; Kline T; Hanson J; Li X; Zhou S; Wells JA; Sato AK; Renslo AR Mol Pharm; 2018 May; 15(5):2054-2059. PubMed ID: 29569925 [TBL] [Abstract][Full Text] [Related]
14. Introduction to Antibody-Drug Conjugates. Pettinato MC Antibodies (Basel); 2021 Oct; 10(4):. PubMed ID: 34842621 [TBL] [Abstract][Full Text] [Related]
15. Engineered cysteine antibodies: an improved antibody-drug conjugate platform with a novel mechanism of drug-linker stability. Sussman D; Westendorf L; Meyer DW; Leiske CI; Anderson M; Okeley NM; Alley SC; Lyon R; Sanderson RJ; Carter PJ; Benjamin DR Protein Eng Des Sel; 2018 Feb; 31(2):47-54. PubMed ID: 29370435 [TBL] [Abstract][Full Text] [Related]
16. A Polar Sulfamide Spacer Significantly Enhances the Manufacturability, Stability, and Therapeutic Index of Antibody-Drug Conjugates. Verkade JMM; Wijdeven MA; Van Geel R; Janssen BMG; Van Berkel SS; Van Delft FL Antibodies (Basel); 2018 Feb; 7(1):. PubMed ID: 31544864 [TBL] [Abstract][Full Text] [Related]
17. Linker Design Impacts Antibody-Drug Conjugate Pharmacokinetics and Efficacy Su D; Zhang D Front Pharmacol; 2021; 12():687926. PubMed ID: 34248637 [TBL] [Abstract][Full Text] [Related]
18. Effects of Drug-Antibody Ratio on Pharmacokinetics, Biodistribution, Efficacy, and Tolerability of Antibody-Maytansinoid Conjugates. Sun X; Ponte JF; Yoder NC; Laleau R; Coccia J; Lanieri L; Qiu Q; Wu R; Hong E; Bogalhas M; Wang L; Dong L; Setiady Y; Maloney EK; Ab O; Zhang X; Pinkas J; Keating TA; Chari R; Erickson HK; Lambert JM Bioconjug Chem; 2017 May; 28(5):1371-1381. PubMed ID: 28388844 [TBL] [Abstract][Full Text] [Related]
19. Antibody drug conjugates: design and selection of linker, payload and conjugation chemistry. McCombs JR; Owen SC AAPS J; 2015 Mar; 17(2):339-51. PubMed ID: 25604608 [TBL] [Abstract][Full Text] [Related]
20. Current methods for the synthesis of homogeneous antibody-drug conjugates. Sochaj AM; Świderska KW; Otlewski J Biotechnol Adv; 2015 Nov; 33(6 Pt 1):775-84. PubMed ID: 25981886 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]